Home | Welcome to Contract Pharma   
Last Updated Thursday, April 24 2014
Print

Ligand Earns Milestone for Kyprolis Sales



By Kristin Brooks



Published February 11, 2014
Ligand Pharmaceuticals, Inc. has earned $1 million commercial milestone payment from Onyx Pharmaceuticals, a subsidiary of Amgen, triggered by the achievement of more than $250 million of annual product sales of Kyprolis in 2013.
 
Ligand receives royalties for Kyprolis and is eligible to receive additional commercial and regulatory milestones. Kyprolis is indicated to treat multiple myeloma and was received accelerated approval from FDA in July 2012.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On